A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
2期
已完成
NCT04718896
| 适应症 | Moderate to Severe Plaque Psoriasis |
|---|
| 分期 | 2期 |
|---|
| 申办方 | UCB Biopharma SRL |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 41 人 |
|---|
| 干预（药物） | bimekizumab |
|---|
| 开始日期 | 2021年4月6日 |
|---|
| 完成日期 | 2025年3月12日 |
|---|
| 结果公布日 | 2026年5月18日 |
|---|
摘要
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Plasma Concentration of Bimekizumab at Week 0
Baseline (Week 0) · microgram per milliliter (µg/mL)
| BKZ Dose A (320/160 mg) | NA ± NA microgram per milliliter (µg/mL) |
|---|
| BKZ Dose B (64/32 mg) | NA ± NA microgram per milliliter (µg/mL) |
|---|
Plasma Concentration of Bimekizumab at Week 1
Week 1 · µg/mL
| BKZ Dose A (320/160 mg) | 21.145 ± 33.510 µg/mL |
|---|
| BKZ Dose B (64/32 mg) | 3.811 ± 30.424 µg/mL |
|---|
Plasma Concentration of Bimekizumab at Week 4
Week 4 · µg/mL
| BKZ Dose A (320/160 mg) | 11.718 ± 35.259 µg/mL |
|---|
| BKZ Dose B (64/32 mg) | 1.986 ± 22.888 µg/mL |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。